All In Biotech

Drug Trial Radar · NCT04848493

National Project on Vaccines, COVID-19 and Frail Patients

A National, Multicentric, Observational, Prospective Study to Assess Immune Response to COVID-19 Vaccine in Frail Patients (VAX4FRAIL).

Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

747

Actual

Start

Apr 19, 2021

Primary completion

May 16, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Azienda USL Reggio Emilia - IRCCSGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Istituto Clinico Humanitas; IRCCS San Raffaele; Regina Elena Cancer Institute; Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS; University of Roma La Sapienza; Fondazione IRCCS Policlinico San Matteo di Pavia; Istituti Fisioterapici Ospitalieri; Istituti Tumori Giovanni Paolo II; Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna
First posted
Apr 19, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre observational study with the aim of evaluating the antibody and cellular response after vaccination for SARS-CoV-2 with Pfizer-BioNTech or Moderna vaccines in frail subjects with impaired immuno-competence, due to their underlying diseases or ongoing therapies.

Conditions

  • COVID-19
  • Solid Tumor
  • Hematologic Diseases
  • Neurologic Disorder
  • Rheumatic Diseases

Interventions

  • COVID-19 vaccinesBiological

    This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SARS-CoV-2 vaccine immunizationTime frame: 5-7 weeks after T0 for Pfizer/BioNTech vaccination; 6-8 weeks after T0 for Moderna vaccination

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • IRCCS Istituto Tumori Giovanni Paolo II

    Bari, Bari, Italy

  • IRCCS Azienda Ospedaliera Universitaria

    Bologna, Bologhna, Italy

  • Ospedale Policlinico San Martino IRCCS

    Genova, Genova, Italy

  • Foindazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Milano, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Milano, Italy

  • IRCCS Istituto Clinico Humanitas

    Milan, Milano, Italy

  • IRCCS Ospedale San Raffaele

    Milan, Milano, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Pavia, Italy

  • Azienda USL IRCCS di Reggio Emilia

    Reggio Emilia, Reggio Emilia, Italy

  • IRCCS Istituto Nazionale Tumori Regina Elena

    Roma, Roma, Italy

  • IRCCS Istituto per le Malattie Infettive Lazzaro Spallanzani

    Roma, Roma, Italy

  • Istituto Dermatologico San Gallicano

    Roma, Roma, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.